AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcus Biosciences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate domvanalimab (AB154), Arcus's investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Imfinzi is the only im

Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus's Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC

Pfizer

These leaders in the coronavirus vaccine race have other things to offer investors.

Got $1,000? These 2 Top Stocks Are Great Buys Right Now

Operation Warp Speed is reupping with this partner to prove long-lasting prevention is better than treatment.

Move Over, Regeneron! Operation Warp Speed Has a New Partner

Johnson & Johnson

Some things have changed, but others haven't.

AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race

JPMorgan Chase & Co

Procter & Gamble

Starbucks

As market valuations look stretched, its a good time to consider exposure to some low beta safe stocks that feature dependable dividends. The post 4 Safe Stocks to Lock Down Profits appeared first on InvestorPlace.

4 Safe Stocks to Lock Down Profits

Vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups

Oxford Covid vaccine works in all ages, trials suggest

BioNTech SE

CureVac B.V

Inovio Pharmaceuticals

Moderna

Novavax

The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.

Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact

Will the Coronavirus Vaccine Market Be Winner-Take-All?

AstraZeneca posted positive interim Phase 2 testing data on its Covid-19 vaccine candidate in older adults, while Moderna inked a supply contract with Qatar, as MRNA stock, AZN stock rose. The post Covid Roundup: AstraZeneca Reports Positive Covid-19 Vaccine Data; Moderna Inks New Supply Deal appeared first on Investor's Business Daily.

Covid Roundup: AstraZeneca Reports Positive Covid-19 Vaccine Data; Moderna Inks New Supply Deal

Interim results suggest the group at highest risk from the virus could build immunity.

AstraZeneca's COVID-19 vaccine trials offer hope for older adults

What's the Best Way to Invest in Coronavirus Vaccine Stocks?

The announcement is likely to boost hopes of a Covid vaccine being developed before the end of the year.

Oxford-AstraZeneca coronavirus vaccine reportedly triggers immune response among adults

Data from AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine trial, developed in collaboration with the University of Oxford, has shown encouraging signs for the elderly, the Financial Times reports. Researchers found that the vaccine triggers protective antibodies and T-cells in people aged over 55, which are among the most vulnerable to the coronavirus.

AstraZeneca COVID-19 Vaccine Data Shows Promising Signs In Older Age Group: FT

The coronavirus vaccine candidates attempt to trick the body in different ways.

What Are the Differences Between the Leading Coronavirus Vaccine Candidates?

Sanofi

As we (hopefully) approach the finish line in the COVID-19 vaccine race, it's a wonderful time to buy shares of Novavax and Sanofi.

2 Surefire Coronavirus Stocks to Buy Right Now

The upside is huge, but the risks could be larger than normal.

Are Consumers and Investors Protected Against COVID-19 Vaccine Risks?

AstraZeneca Plc said on Friday its coronavirus vaccine deal with Oxford University will allow it to add up to 20% of manufacturing costs to cover additional expenses required to be incurred by the British drugmaker.

AstraZeneca says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs

The US has allowed a major coronavirus vaccine trial to resume. The Food and Drug Administration has allowed a COVID-19 vaccine trial commissioned by AstraZeneca and the University of Oxford to resume within the US, according to a Wall Street Journal report. 

AstraZeneca's coronavirus vaccine trial can continue in the US after being halted due to a participant having a 'serious adverse reaction' (AZN)

Shares of AstraZeneca were up 0.8% in trading on Friday after a person familiar with the matter told The Wall Street Journal that the company's COVID-19 vaccine trial will resume in the U.S. The Phase 3 clinical trial for the vaccine candidate that the company is developing with the University of Oxford was placed on hold in multiple countries over concern about an unexplained illness. The trial has already been restarted in the U.K. According to the WSJ report, the Food and Drug Administration contacted the company on Friday to let it know it can resume the study in the U.S. AstraZeneca's coronavirus vaccine candidate is one of four COVID-19 vaccines in late-stage development in the U.S. The company's U.S. traded stock is up 4.6% for the year, while the S&P 500 has gained 6.9%.

WSJ: AstraZeneca can resume COVID-19 vaccine trial in the U.S.

Abbott Labs

You can probably hold onto these winners beyond 2030.

Have $1,000? 2 Fantastic Coronavirus Stocks to Buy and Hold for the Next Decade

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community. The program seeks to shine a light upon unsung community heroes who often go unrecognized by traditional awards programs and this year saw nominations from 31 states. “T

AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards

The COVID-19 vaccine being developed by Oxford University and AstraZeneca has been shown to work as planned by new analysis.

Oxford-AstraZeneca vaccine 'behaves as desired'

The fatality is the latest setback for AZD1222, developed in coordination with the University of Oxford.

Brazil Healthcare Regulator Says Patient in AstraZeneca Coronavirus Vaccine Trial Dies

Brazilian newspaper O Globo reported that a participant in a Phase 3 trial for a COVID-19 vaccine has died. What Happened: The Brazilian Health Authority Anvisa said testing will continue.

Participant In AstraZeneca, Oxford University COVID-19 Vaccine Trial Dies

News for AstraZeneca Stock (AZN)